RED: hospital use only.
(Remicade (reference infliximab product), Remsima and Inflectra (biosimilars) are available for use as per NICE TA329 - Ulcerative Colitis and NICE TA373 - RA) (Decision date - March 2015)
RED:1,2,3 NICE TA375 for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. (Decision date - February 2016)
RED1,2,3: NICE TA383 for ankylosing spondylitis and non-radiographic axial spondyloarthritis. (Decision date - March 2016)
RED1,2,3: NICE TA715: Adalimumab, etanercept and infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. (Decision date - August 2021)